Immune evasion of tumor cells using membrane-bound complement regulatory proteins
- 1 December 1999
- journal article
- review article
- Published by Elsevier in Immunology Today
- Vol. 20 (12), 576-582
- https://doi.org/10.1016/s0167-5699(99)01537-6
Abstract
No abstract availableThis publication has 58 references indexed in Scilit:
- Mechanisms of in vivo antineuroblastoma activity of human natural IgMEuropean Journal Of Cancer, 1997
- Tumour necrosis factor‐α up‐regulates decay‐accelerating factor gene expression in human intestinal epithelial cellsImmunology, 1997
- A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitroEuropean Journal of Immunology, 1996
- Down-Regulation of CD59 (Protectin) Expression on Human Colorectal Adenocarcinoma Cell Lines by LevamisoleScandinavian Journal of Immunology, 1995
- The Influence of Tumour Necrosis Factor‐γ, Interleukin‐1β and Interferon‐γ on the Expression and Function of the Complement Regulatory Protein CD59 on the Human Colonic Adenocarcinoma Cell Line HT29Scandinavian Journal of Immunology, 1995
- Expression and function of CD59 on colonic adenocarcinoma cellsEuropean Journal of Immunology, 1994
- Activation of human complement by mouse and mouse/human chimeric monoclonal antibodiesClinical and Experimental Immunology, 1993
- A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2aCancer Immunology, Immunotherapy, 1992
- Complement killing of human neuroblastoma cells: A cytotoxic monoclonal antibody and its F(ab)'2-cobra venom factor conjugate are equally cytotoxicMolecular Immunology, 1990
- Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cellsClinical Immunology and Immunopathology, 1987